- Q1 2024 AIM ImmunoTech Inc Earnings Call TranscriptMay 16, 2024€0.364 (+0.55%)Earnings
- Q4 2023 AIM ImmunoTech Inc Earnings Call TranscriptApr 02, 2024€0.452 (+5.12%)Earnings
- AIM ImmunoTech Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Q2 2023 AIM ImmunoTech Inc Earnings Call TranscriptAug 15, 2023€0.57 (+7.55%)Earnings
- AIM ImmunoTech Inc Investor Summer Spotlight Series TranscriptJul 12, 2023
- Q1 2023 AIM ImmunoTech Inc Earnings Call TranscriptMay 16, 2023€0.372 (-6.53%)Earnings
- Q4 2022 AIM ImmunoTech Inc Earnings Call TranscriptApr 03, 2023€0.39 (+1.38%)Earnings
- AIM ImmunoTech Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- AIM ImmunoTech Inc at JTC Team Top Picks Virtual Investor Conference TranscriptJan 26, 2022
- AIM ImmunoTech Inc at SNN Network Virtual Conference TranscriptAug 03, 2020
- AIM ImmunoTech on Commercial Launch in Argentina for Chronic Fatigue and COVID-19 Clinical Trials- Corporate Analyst Meeting TranscriptJul 31, 2020
- CEO Roadshow Interview: Thomas Equels, CEO of AIM Immunotech Corporate Analyst Meeting TranscriptJun 24, 2020
- AIM ImmunoTech greenlit to import chronic fatigue syndrome drug into Argentina Corporate Analyst Meeting TranscriptJun 22, 2020
- AIM ImmunoTech Inc To Describe Their Approach and Progress with Ampligen to Combat COVID-19 TranscriptMay 28, 2020
- AIM ImmunoTech Inc at SNN Planet MicroCap Showcase TranscriptApr 22, 2020
CEO Roadshow Interview: Thomas Equels, CEO of AIM Immunotech Corporate Analyst Meeting Transcript
Hi, I am Mike Elliott and you're watching CEO Roadshow. Today, we're joined by Mr. Thomas Equels, he is CEO of AIM Immunotec, an immuno pharma company, focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. They trade under the ticker AIM. Good morning, Tom. Great to have you back on the show.
Good to be here, Mike, pleasure to see you again.
So I first, can you just tell us -- let's start off by your -- with your latest news, which came out last week regarding FDA authorization for the first human trial assessing the safety and effectiveness of Ampligen in cancer patients with COVID-19. Tell us more about that.
Well, we're very excited about that because we have established a strong position
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)